Cardarine (GW-501516) vs Semaglutide
A side-by-side research comparison of Cardarine (GW-501516) and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardarine (GW-501516) | Semaglutide |
|---|---|---|
| Full name | GW-501516 (Cardarine, Endurobol) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Discontinued in development (safety concerns; banned in sport) | FDA Approved |
| Mechanism | Activates the PPAR-delta nuclear receptor, shifting cells toward burning fat for fuel and upregulating genes involved in fatty-acid oxidation and endurance metabolism. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 453.50 Da | 4,114 Da |
| Half-life | ~20-24 hours | 7 days (168 hours) |
| Bioavailability | Oral | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | Commonly cited 10-20 mg/day (research) | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous injection |
Cardarine (GW-501516) reported benefits
- Increased endurance (research claims)
- Enhanced fat oxidation
- No hormonal suppression
- Improved lipid profile in some studies
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.